p21(Waf1/Cip1) and p53 protein expression in breast cancer

American Journal of Clinical Pathology

Volumn 107, Issue 6, 1997, Pages 684-691

  Wakasugi, Eijiro ^a   Kobayashi, Tetsuro ^b   Tamaki, Yasuhiro ^a   Ito, Yasuhiro ^a   Miyashiro, Isao ^a   Komoike, Yoshifumi ^a   Takeda, Tsutomu ^a   Shin, Eisei ^b   Takatsuka, Yuichi ^c   Kikkawa, Nobuteru ^b   Monden, Takushi ^a   Monden, Morito ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b OSAKA NATIONAL HOSPITAL   (Japan)

^c KANSAI ROSAI HOSPITAL   (Japan)

Author keywords

Breast cancer; Cip1; Immunohistochemistry; p53; Waf1; Western blotting

Indexed keywords

PROTEIN P21; PROTEIN P53;

ANALYTIC METHOD; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER SURVIVAL; CELL CYCLE G1 PHASE; DNA DAMAGE; GENE MUTATION; HUMAN; HUMAN TISSUE; MEDIATOR RELEASE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TUMOR GROWTH;

EID: 0031004664     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/107.6.684     Document Type: Article

References (50)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49-53.
2. Cattoretti G, Rilke F, Andreola S, D'Amato L, Della D. p53 expression in breast cancer. Int J Cancer. 1988;41:178-183.
3. Campo E, Calle-Martin O, Miquel R, et al. Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinoma. Cancer Res. 1991;51:4436-4442.
4. Bonder SM, Minna JD, Jensen SM, et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene. 1992;7:743-749.
5. Marchetti A, Buttitta F, Pellegrini S, et al. p53 mutations and histological type of invasive breast carcinoma. Cancer Res. 1993;53:4665-4669.
6. Singh S, Simon M, Meybohm I, et al. Human breast cancer: frequent p53 allele loss and protein overexpression. Hum Genet. 1993;90:635-640.
7. Wagata T, Shibagaki I, Imamura M, et al. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinoma. Cancer Res. 1993;53:846-850.
8. Umekita Y, Kobayashi K, Saheki T, Yoshida H. Nuclear accumulation of p53 protein correlates with mutations in the p53 gene on archival paraffin-embedded tissues of human breast cancer. Jpn J Cancer Res. 1994;85:825-830.
9. Iwaya K, Tsuda H, Hiraide H, et al. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res. 1991;82:835-840.
10. Ostrowski JL, Sawan A, Henry L, et al. p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol. 1991;164:75-81.
11. Thompson AM, Anderson TJ, Condie A, et al. p53 allele losses, mutations and expression in breast cancer and their relationship to clinicopathological parameters. Int J Cancer. 1992;50:528-532.
12. Friedrich K, Gluba S, Eidtmann H, Jonat W. Overexpression of p53 and prognosis in breast cancer. Cancer. 1993;72:3641-3647.
13. Martinazzi M, Crivelli F, Zampatti C, Martinazzi S. Relationship between p53 expression and other prognostic factors in human breast carcinoma: an immunohistochemical study. Am J Clin Pathol. 1993;100:213-217.
14. Tsuda H, Hirohashi S. Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotype in breast cancer. Int J Cancer. 1994;57:498-503.
15. Ohue M, Tomita N, Monden T, et al. A frequent alteration of p53 gene in carcinoma in adenoma of colon. Cancer Res. 1994;54:4798-4804.
16. Sawan A, Randell B, Angus B, et al. Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: an immunohistochemical study. J Pathol. 1992;168:23-28.
17. Thor A, Moore DH, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst. 1992;84:845-854.
18. Lipponen P, Ji H, Aaltomma S, Syrjanen S, Syrjanen K. p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer. 1993;55:51-56.
19. Elledge RM, Allred DC. The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat. 1994;32:39-47.
20. Caleffi M, Teague MW, Jensen RA, Vnencak-Jones CL, Dupont WD, Parl FF. p53 gene mutations and steroid receptor status in breast cancer: clinicopathologic correlations and prognostic assessment. Cancer. 1994;73:2147-2156.
21. Gohring UJ, Scharl A, Heckel C, Ahr A, Crombach G. p53 protein in 204 patients with primary breast carcinoma: immunohistochemical detection and clinical value as a prognostic factor. Arch Gynecol Obstet. 1995;256:139-146.
22. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991;51:6304-6311.
23. Kastan MB, Zhan Q, El-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cancer Res. 1992;71:587-597.
24. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 1993;362:847-849.
25. Clarke AR, Puridie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 1993;362:849-852.
26. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potent inhibitor of p53 tumor suppression. Cell. 1993;75:817-825.
27. 1 cyclin-dependent kinases. Cell. 1993;75:805-816.
28. Akiyama T, Ohuchi T, Sumida S, Matsumoto K, Toyoshima K. Phosphorylation of the retinoblastoma protein by cdk2. Proc Natl Acad Sci USA. 1992;89:7900-7904.
29. Kitagawa M, Saitoh S, Ogino H, et al. cdc2-like kinase is associated with the retinoblastoma protein. Oncogene. 1992;7:1067-1074.
30. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer. 1957;11:359-377.
31. Kawasaki Y, Monden T, Morimoto H, et al. Immunohistochemical study of p53 expression in microwave-fixed, paraffin-embedded sections of colorectal carcinoma and adenoma. Am J Clin Pathol. 1992;97:244-249.
32. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
33. Cox DR. Regression models life tables (with discussion). J R Stat Soc. 1972;34:187-202.
34. McGuire WL, Dressler LG. Emerging impact of flow cytometry in predicting recurrence and survival in breast cancer patients. J Natl Cancer Inst. 1985;75:405-410.
35. Barnard N, Hall PA, Lemoine NR, Kadar N. Proliferative index in breast carcinoma determined in situ by Ki-67 immunostaining and its relationship to clinical and pathological variables. J Pathol. 1987;152:287-295.
36. Lelle RJ, Heidenreich W, Stauch G, Gerdes J. The correlation of growth fractions with histological grading and lymph node status in human mammary carcinoma. Cancer. 1987;59:83-87.
37. Kallioniemi O-P, Blanco G, Alavaikko M, et al. Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction: a proposed classification of DNA histograms in breast cancer. Cancer. 1988;62:2183-2190.
38. Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T, Merkel D. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Cytometry. 1993;14:482-485.
39. Betta PG, Bottero G, Pavesi M, Pastormerlo M, Bellinger D, Tallarida F. Cell proliferation in breast carcinoma assessed by a PCNA grading system and its relation to other prognostic variables. Surg Oncol. 1993;2:59-63.
40. Thomas M, Noguchi M, Kitagawa H, Kinoshita K, Miyazaki Y. Poor prognostic value of proliferating cell nuclear antigen labelling index in breast carcinoma. J Clin Pathol. 1993;46:525-528.
41. Gasparini G, Boracchi P, Verderio P, Bevilacqua P. Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. Int J Cancer. 1994;57:822-829.
42. Martinez J, Georgoff I, Levine AJ. Cellular localization and cell cycle regulation by a temperature sensitive p53 protein. Genes Dev. 1991;5:151-159.
43. Mercer WE, Shields MT, Amin M. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci USA. 1990;87:6166-6170.
44. Weinberg RA. Tumor suppressor genes. Science. 1991;254:1138-1146.
45. Coulter LK, Wolber R, Tron VA. Site-specific comparison of p53 immunostaining in squamous cell carcinomas. Hum Pathol. 1995;26:531-533.
46. Michieli P, Chedid M, Lin D, et al. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 1994;54:3391-3395.
47. DiGiuseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol. 1995;147:884-888.
48. Thomas DW. p53 in tumour pathology: can we trust immunocytochemistry? J Pathol. 1992;166:329-330.
49. Rubio M-P, Deimling A, Yandell DW, Wiestler OD, Gusella JF, Louis DN. Accumulation of wild type p53 protein in human astrocytomas. Cancer Res. 1993;53:3465-3467.
50. Jacquemier J, Moles JP, Penault-Liarca F, et al. p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer. 1994;69:846-852.